From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley’s most influential VCs.
Chai Discovery
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.